Blood disorders, particularly malignant cancers, represent an enormous economic burden to the European economy, and to "society overall."
Achieving a negative margin may be essential for optimizing both local control and survival in patents with soft tissue sarcoma treated with radiotherapy.
The U.S. Food and Drug Administration (FDA) denied approval to the biosimilar pegfilgrastim candidate developed by Sandoz.
Nivolumab induced frequent responses with an acceptable safety profile for patients with classical Hodgkin lymphoma.
Geographic location may be a causal factor for the development of basal cell carcinoma (BCC).
The U.S. Food and Drug Administration granted Orphan Drug Designation to TK216 for the treatment of Ewing sarcoma.
The combination of filanesib, bortezomib, and dexamethasone appears to have durable activity in multiple myeloma.
Aldoxorubicin may be more efficacious for the treatment of soft tissue sarcoma (STS).
Tumor vaccines and cellular immunotherapies may improve overall and progression-free survival of patients with non-small cell lung cancer (NSCLC).
Even a high-fat Mediterranean diet may protect against breast cancer, diabetes, and cardiovascular disease.
New cases of metastatic prostate cancer in the United States have increased 72 percent in the past decade.
The phase 3 GOYA study for patients with previously untreated diffuse large B-cell lymphoma (DLBCL) failed to meet its primary endpoint.
Treatment with ceritinib induced responses in patients with ALK-rearranged non-small cell lung cancer (NSCLC).
Veliparib and carboplatin may together be an effective treatment for patients with clinical stage II or II breast cancer.
Acquired resistance to PD-1 blockade immunotherapy of patients with melanoma may be associated with defects in the pathways.
Dopamine antagonist olanzapine prevents nausea and the complete response rate among previously untreated patients receiving highly emetogenic chemotherapy.
Administration of the anti-CTLA-4 antibody ipilimumab is feasible for patients with recurrent hematologic malignancies.
Researchers may have detected a gene that, if targeted by a drug, may increase the effectiveness of multiple myeloma (MM) treatment.
Many patients with advanced cancer receiving anti-PD-1 or anti-PD-L1 treatment have papular and nodular eruptions with scale with lichenoid features.
TAS-102 improved survival, when contrasted with placebo, for patients with refractory colorectal cancer, though the drug showed no activity for the second-line treatment of patients with small cell lung cancer.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Era of Precision Oncology for Prostate Cancer 'Is Upon Us'
- Veliparib and Carboplatin May Be Effective Against Triple-negative Breast Cancer
- Metastatic Prostate Cancer Cases On the Rise in the U.S.
- Some Patients With Locally Advanced Rectal Cancer May Avoid Surgery
- Some Patients With Endocrine-responsive Early-stage Breast Cancer May Avoid Chemotherapy
- Breast Cancer (Invasive) Treatment Regimens
- Breast Cancer (Recurrent or Metastatic) Treatment Regimens
- TRUS-biopsy Poorly Detects Prostate Cancer
- Model Predicts That Healthful Lifestyle Benefits Women at Risk of Breast Cancer
- Mental Disorder Risk High Among Patients With Cancer During Treatment and Before Diagnosis
- Life Expectancy of Patients With CML Greatly Improved, but at What Cost?
- Costs of Malignant Blood Disorders in European Countries Reached €23 Billion in 2012
- Achieving Negative Margin Essential for Optimizing Local Control, Survival in Sarcoma
- Is BRCA1/2 Genetic Counseling by Telephone Inferior to a Face-to-face Interaction?
- FDA Declines to Approve Pegfilgrastim Biosimilar